Hormonal
GLP-1 receptor agonists provide neuroprotective benefits, including potential improvement in cognitive function and reduction in neurodegenerative disease progression (Alzheimer's and Parkinson's).
GLP-1 RAs are being studied for their potential to protect the brain in Alzheimer's and Parkinson's disease. They may reduce inflammation and oxidative stress in the brain. While not yet a standard treatment for these conditions, the biological plausibility is strong, and patients with these diseases should discuss the potential benefits with their neurologist.
GLP-1RA also minimizes oxidative stress... Furthermore, the expression of Brain-Derived Neurotrophic factor (BDNF) is enhanced... GLP-1RA can reverse key pathophysiological features like amyloid b protein and tau hyperphosphorylation
Why this rating
Evidence is largely from preclinical studies and small clinical trials; large-scale definitive clinical trials for neurodegenerative diseases are still emerging.
Source
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Bisma Fatima Hammad et al. · Frontiers in Clinical Diabetes and Healthcare · 2025
DOI 10.3389/fcdhc.2025.1590530
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk.Strong
- GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →